Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment

Curr Top Med Chem. 2021;21(31):2771-2777. doi: 10.2174/1568026621666210920154942.

Abstract

The polycomb repressive complex 2 (PRC2) can methylate at lysine 27 of histone H3 at the trimethylation level (H3K27me3). This leads to gene silencing and is known to be dysregulated in many cancers. PRC2 is made up of three core subunits: EZH2, SUZ12, and EED. EED is essential for the regulation of PRC2 function by binding to H3K27me3. Targeting the allosteric site within EED offers new strategies to disrupt the PRC2 activity. In this minireview, we summarize some of the recent developments in small molecules that target EED and its interaction with other core proteins in the PRC2 complex.

Keywords: Cancer; Degrader.; EED; EZH2; Inhibitor; PRC2.

Publication types

  • Review

MeSH terms

  • Allosteric Site
  • Animals
  • Histones / chemistry
  • Histones / metabolism
  • Humans
  • Methylation
  • Molecular Targeted Therapy*
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism*
  • Polycomb Repressive Complex 2 / antagonists & inhibitors*
  • Polycomb Repressive Complex 2 / chemistry
  • Polycomb Repressive Complex 2 / metabolism

Substances

  • EED protein, human
  • Histones
  • Polycomb Repressive Complex 2